Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

Rhea-AI Summary

Curis (NASDAQ: CRIS) will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025 at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.

Participants can join by dialing (800) 836-8184 (U.S.) or (646) 357-8785 (international), via the live audio webcast linked from the company's events & presentations page, and a replay will be available at www.curis.com.

LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the events & presentations section of the Curis website. A replay of the conference call will be available at www.curis.com.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-third-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-6-2025-302600252.html

SOURCE Curis, Inc.

FAQ

When will Curis (CRIS) report third quarter 2025 results?

Curis will report third quarter 2025 financial and operating results on November 6, 2025 at 4:00 p.m. ET.

What time is the Curis (CRIS) conference call and webcast on November 6, 2025?

Management will host the conference call and simultaneous webcast on November 6, 2025 at 4:30 p.m. ET.

How can investors join the Curis (CRIS) November 6, 2025 call?

Dial (800) 836-8184 from the U.S. or (646) 357-8785 from other locations, or access the live audio webcast via the company's events & presentations page.

Will a replay of the Curis (CRIS) November 6, 2025 call be available?

Yes. A replay of the conference call will be available at www.curis.com.

What will Curis (CRIS) report on November 6, 2025?

Curis will report its third quarter 2025 financial and operating results and host a management conference call and webcast.